FDA Delays Decision on Gilead’s Truvada to Prevent HIV

Gilead Sciences Inc., the world’s largest maker of AIDS drugs, said U.S. regulators delayed by three months a decision on whether the company can expand use of its HIV treatment Truvada as a therapy to prevent the virus.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.